About the Connective Tissue Disease - Interstitial Lung Disease (CTD-ILD) Working Group
Interstitial lung diseases (ILD), including those related to connective tissue disease (CTD), and idiopathic pulmonary fibrosis (IPF) carry high morbidity and mortality.
Great efforts are under way to develop and investigate meaningful treatments in the context of clinical trials. However, efforts have been challenged by a lack of validated outcome measures and by inconsistent use of measures in clinical trials.
Dinesh Khanna
Co-Chair
Sydney Montesi
Co-Chair
Susanna Proudman
Co-Chair
David Roofeh
Fellow
Sirus Jesudasen
Fellow
Technical Advisory Group Instrument Townhall Presentation from the CTD-ILD group of their Instruments for Lung Physiology
OMERACT Endorsed Core Domain Set Clinical Trials in Connective Tissue Disease - Interstitial Lung Disease (CTD-ILD)
OMERACT INSTRUMENT SELECTION CERTIFICATES
Working Group Publications
Outcome measurement instrument selection for lung physiology in systemic sclerosis associated interstitial lung disease: A systematic review using the OMERACT filter 2.1 process
Connective Tissue Disease-associated Interstitial Lung Diseases (CTD-ILD) — Report from OMERACT CTD-ILD Working Group
Reconciling Healthcare Professional and Patient Perspectives in the Development of Disease Activity and Response Criteria in Connective Tissue Disease–related Interstitial Lung Diseases
Working Group Members:
Prof. Dinesh Khanna
Prof. Joanna Porter
Puja Mehta
David Roofeh
Jeff Swirgis
Toby Maher
Fernando Martinez
Chris Denton
Kevin Brown
Peter Tugwell